<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00387270</url>
  </required_header>
  <id_info>
    <org_study_id>DIM03</org_study_id>
    <secondary_id>DIMOND</secondary_id>
    <nct_id>NCT00387270</nct_id>
  </id_info>
  <brief_title>Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease</brief_title>
  <official_title>A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huntington Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medivation, Inc.</source>
  <brief_summary>
    <textblock>
      This study is being conducted to determine the safety and tolerability of Dimebon in people
      with Huntington's disease after short-term exposure (one week) and after longer exposure
      (three months). Also, the study will assess whether or not there is an effect of Dimebon on
      the symptoms of Huntington's disease, including cognitive (thinking abilities), motor
      (movement), behavior, and overall functioning.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Huntington's Disease Rating Scale</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dimebon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimebon</intervention_name>
    <description>Dimebon 10 or 20 mg TID x 7 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical features of Huntington's disease and a confirmatory family history of HD, or
             a CAG repeat expansion greater than or equal to 36

          -  Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the
             Unified Huntington's Disease Rating Scale

        Exclusion Criteria:

          -  Clinical evidence of unstable medical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl D Kieburtz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester Medical School, Huntington Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntington Study Group</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.huntington-study-group.org</url>
    <description>The Huntington Study Group (HSG) is a non-profit group of physicians and other health care providers from medical centers in the U.S., Canada, Europe, and Australia, experienced in the care of Huntington patients and dedicated to clinical research of HD</description>
  </link>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2006</study_first_posted>
  <last_update_submitted>January 3, 2008</last_update_submitted>
  <last_update_submitted_qc>January 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Karl Kieburtz, MD</name_title>
    <organization>Clinical Trial Coordination Center</organization>
  </responsible_party>
  <keyword>Huntington's disease</keyword>
  <keyword>Dimebon</keyword>
  <keyword>dose-escalation</keyword>
  <keyword>Phase 1-2a</keyword>
  <keyword>randomized</keyword>
  <keyword>controlled</keyword>
  <keyword>double-blind</keyword>
  <keyword>Unified Huntington's Disease Rating Scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

